Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a downside of -6.96% to close Tuesday at $1.47 after subtracting -$0.11 on the day. The 5-day average trading volume is 1,688,100 shares of the company’s common stock. It has gained $1.8600 in the past week and touched a new high 1 time within the past 5 days. An average of 1,761,875 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,273,862.
KPTI’s 1-month performance is -9.82% or -$0.1900 on its low of $1.4600 reached on 08/22/23. The company’s shares have touched a 52-week low of $1.44 and high of $6.01, with the stock’s rally to the 52-week high happening on 04/17/23. YTD, KPTI has lost -56.76% or -$1.9300 and has reached a new high 13 times. However, the current price is down -75.54% from the 52-week high price.
Insider Transactions
KPTI stock investors last saw insider trading activity on Aug 07.Paulson Richard A. (President and CEO) most recently sold 3,722 shares at $1.72 per share on Aug 07. This transaction cost the insider $6,402. EVP, Chief Development Officer, Poulton Stuart, sold 2,845 shares at a price of $1.70 on Jul 28. Then, on Jul 05, President and CEO Paulson Richard A. sold 3,538 shares at a price of $1.72 per share. This transaction amounted to $6,085.
Valuation Metrics
KPTI stock has a beta of -0.02. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.17.
Karyopharm Therapeutics Inc.’s quick ratio for the recent period was 4.90, with the current ratio over the same period at 4.90.. In terms of profitability, the gross margin trailing 12 months is 96.30%. The trailing 12-month EBITDA margin is -90.14%. The firm’s gross profit as reported stood at $151.86 million against revenue of $157.07 million.
Earnings Surprise
Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -50.35% to -$32.63 million, while revenue of -$34.13 million was -4.6% off the previous quarter. EBITDA for the quarter stood at more than -$30.31 million. KPTI stock balance sheet for the recent quarter shows that total liabilities totaled 369.08 million, with total debt at $310.8 million. Shareholders hold equity totaling $114.36 million.
Let’s look briefly at Karyopharm Therapeutics Inc. (KPTI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 27.14% to suggest the stock is trending oversold, with historical volatility in this time period at 53.05%.
The stock’s 5-day moving average is $1.6160, reflecting a -16.48% or -$0.2900 change from its current price. KPTI is currently trading -7.55% above its 20-day SMA, -62.50% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -33.48% and SMA200 by-69.12%.
Stochastic %K and %D was 10.36% and 20.57% and the average true range (ATR) pointed at 0.1228. The RSI (14) points at 33.04%, while the 14-day stochastic is at 2.44% with the period’s ATR at 0.1263. The stock’s 9-day MACD Oscillator is pointing at -0.0889 and -0.0971 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Piper Sandler launched coverage with an Overweight rating. Analysts offering their rating for KPTI stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate KPTI as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 4 have offered a “buy” rating.
